Active Ingredient History
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation. Breast cancer cell growth may be estrogen-dependent. Aromatase (exemestane) is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromatase inhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breast cancer. Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation, an effect also known as "suicide inhibition". Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on the adrenal biosynthesis of corticosteroids or aldosterone. This reduction in serum and tumor concentrations of estrogen delays tumor growth and disease progression. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme. Exemestane is marketed under the trade name Aromasin. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms, Male (Phase 3)
Carcinoma, Intraductal, Noninfiltrating (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Cytochrome P-450 CYP2D6 (Phase 4)
Endometrial Neoplasms (Phase 2)
Fatigue (Phase 3)
Healthy Volunteers (Phase 1)
Hormones (Phase 3)
Hyperplasia (Phase 2)
Kidney Neoplasms (Phase 1)
Lung Neoplasms (Phase 1)
Menopause (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms ()
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 1)
Pharmacokinetics (Phase 1/Phase 2)
Postmenopause (Phase 4)
Progression-Free Survival (Phase 3)
Prostatic Neoplasms (Phase 2)
Quality of Life (Phase 2)
Recurrence (Phase 2)
Sexuality (Phase 4)
Sleep Wake Disorders (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
